Abstract
The identification of biomarkers to select pts most likely to benefit from immunotherapy is still an unmet clinical need. The Meet-URO 18 study is a multicenter study assessing the I-TME in mRCC pts treated with ≥2nd line nivolumab divided according to clinical benefit in responders versus non-responders (progression-free survival ≥ 12 vs ≤ 3 months, respectively).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
